Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
161.40
+0.01 (+0.01%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,547,529
Open
162.00
Bid (Size)
161.31 (1)
Ask (Size)
161.40 (1)
Prev. Close
161.39
Today's Range
161.34 - 163.43
52wk Range
143.13 - 168.85
Shares Outstanding
2,628,679,824
Dividend Yield
2.95%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Today 16:30 EDT
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.
Via
Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
Today 12:14 EDT
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory...
Via
Benzinga
Performance
YTD
+0.89%
+0.89%
1 Month
-0.95%
-0.95%
3 Month
+10.70%
+10.70%
6 Month
+2.03%
+2.03%
1 Year
+2.73%
+2.73%
More News
Read More
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
Today 10:40 EDT
Via
Chartmill
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
September 26, 2024
Via
Benzinga
Why Masimo Stock Crushed the Market Today
September 25, 2024
Via
The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Via
Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
September 23, 2024
Via
Chartmill
The Latest Analyst Ratings For Johnson & Johnson
September 19, 2024
Via
Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
September 21, 2024
Via
The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
September 20, 2024
From
Beasley Allen Law Firm
Via
Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
September 20, 2024
From
Johnson & Johnson
Via
Business Wire
Unpacking the Latest Options Trading Trends in Johnson & Johnson
September 12, 2024
Via
Benzinga
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
September 12, 2024
Via
Benzinga
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
Via
Benzinga
Exposures
Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
Via
Benzinga
Exposures
Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
September 19, 2024
Via
The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
Via
Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
September 17, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
Via
The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
September 12, 2024
Via
Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
September 11, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.